GlassScriptPhysician profile
Nayeem S Akmal
NPI 1124026414
$3,031.57
in general payments reported to CMS, 2019-2025
27 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $58.69 · 2021: $50.80 · 2022: $13.20 · 2023: $596 · 2024: $765 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $317.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $280.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $228.50 | 2019-2025 | |
| Lilly USA, LLC | $223.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $206.89 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.75 | 2020-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $164.48 | 2024-2025 | Veozah |
| Amgen INC. | $123.64 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $123.60 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $122.80 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $108.69 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $107.08 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $75.11 | 2024-2025 | Voquezna |
| Alk-Abello, INC | $48.17 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $46.48 | 2024-2025 | |
| Lundbeck LLC | $43.68 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $43.16 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $38.89 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.97 | 2024 | Caplyta |
| Abbvie INC. | $17.49 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.89 | 2025 | Xifaxan |
| Shield Therapeutics INC | $15.81 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.51 | 2023 | |
| Currax Pharmaceuticals LLC | $14.09 | 2025 | Contrave |
| Insulet Corporation | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayeem Akmal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.